0

Tag: Insulin

Cybersecurity Concerns with Medtronic Insulin Pumps

Insulin pump therapy, or continuous subcutaneous insulin infusion (CSII), has been used in the treatment of diabetes for decades. Devices have evolved with technological advancements; some insulin pumps now feature Bluetooth connectivity and complementary smartphone applications while the use of AI technology is slowly being integrated. Modern insulin pumps are both more patient and physician-friendly as they allow for precise insulin control in diabetic patients.  As a result, the number of pump users has increased manifold now totaling an estimated 350,000 patients within the United States. 

Read more

First “Follow-On” Insulin Now Available in the United States

One year after the US FDA granted approval to the first “follow-on” insulin, the long-acting insulin glargine product has been officially launched in the United States. Approved as a follow-on and not a biosimilar, the long-acting insulin glargine has already been made available in Europe, and is available as a 100 Units/mL strength in 3-mL prefilled pens. It can be used in both children and adults with type 1 diabetes and adults with type 2 diabetes.

References:

Basaglar now available for type 1, type 2 diabetes.

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes.